1,201
Views
39
CrossRef citations to date
0
Altmetric
Review

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials

, , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 555-564 | Received 13 Jun 2018, Accepted 29 Jun 2018, Published online: 13 Jul 2018
 

ABSTRACT

Introduction: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types.

Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients).

Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.

Acknowledgments

We thank Yannick Wirz, MD and Ramon Sager, MD of the Kantonsspital Aarau, Aarau, Switzerland for their assistance with the assessment of the trials included in this analysis. We also thank Prasad Kulkarni, PhD, CMPP of Asclepius Medical Communications LLC, Ridgewood, NJ, USA for editorial assistance, which was funded by bioMérieux.

Declaration of interest

No commercial sponsor had any involvement in design and conduct of this study, namely collection, management, analysis, and interpretation of the data; and preparation, decision to submit, review, or approval of the manuscript. P Schuetz, M Christ-Crain and Mueller received support from Thermo-Fisher and bioMérieux to attend meetings and fulfilled speaking engagements. B Mueller has served as a consultant and received research support. PS also received research support from other diagnostic companies including ROCHE and Abbott. D Stolz and M Tamm received research support from Thermo-Fisher. T Welte and S Schroeder received lecture fees and research support from Thermo-Fisher CE Luyt received lecture fees from Brahms and Merck Sharp & Dohme-Chibret. M Wolff received consulting and lectures fees from Merck Sharp & Dohme-Chibret, Janssen–Cilag, Gilead, Astellas, Sanofi and Thermo-Fisher. Y Shehabi received unrestricted research grants from Thermo-fisher, bioMérieux, Orion Pharma and Pfizer. J-U Jensen declares that he was invited to the European Respiratory Society meeting 2016 by Roche Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Supplementary material

Supplementary data can be accessed here.

Reviewer disclosures

A reviewer on this manuscript has disclosed receipt of honoraria and research report from bioMerieux during the past 5 years, and states this will not influence their review.

Additional information

Funding

This study was supported by an unrestricted research grant from bioMérieux. The funder did not have any role in the interpretation of data.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 866.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.